Analysts Offer Insights on Healthcare Companies: CSL (OtherCMXHF) and Tenet Healthcare (THC)
There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on CSL (CMXHF – Research Report) and Tenet Healthcare (THC – Research Report) with bullish sentiments.
Valentine's Day Sale - 70% Off
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CSL (CMXHF)
In a report released today, David Low from UBS maintained a Buy rating on CSL, with a price target of A$235.00. The company’s shares closed last Wednesday at $119.70.
According to TipRanks.com, Low is ranked #3642 out of 12109 analysts.
CSL has an analyst consensus of Moderate Buy, with a price target consensus of $152.71, a 38.1% upside from current levels. In a report issued on February 2, Citi also maintained a Buy rating on the stock with a A$225.00 price target.
See the top stocks recommended by analysts >>
Tenet Healthcare (THC)
In a report released yesterday, Ryan Langston from TD Cowen maintained a Buy rating on Tenet Healthcare, with a price target of $242.00. The company’s shares closed last Wednesday at $226.35.
According to TipRanks.com, Langston has 0 stars on 0-5 stars ranking scale with an average return of
Tenet Healthcare has an analyst consensus of Strong Buy, with a price target consensus of $244.22, which is a 29.7% upside from current levels. In a report issued on February 2, UBS also maintained a Buy rating on the stock with a $260.00 price target.
